Skip to main content

Table 4 Estimates of diagnostic precision of various markers and outcomes in single studies.

From: Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer

Citation

Marker and Cutpoint

Outcome

Sensitivity

(95% CI)

Specificity

95% CI)

Santolaya 2008

IL8

200

Sepsis

0.49

(0.4 to 0.58)

0.71

(0.67 to 0.75)

Diepold 2008

IL8

30

Prolonged illness

0.87

(0.78 to 0.93)

0.61

(0.42 to 0.76)

Diepold 2008

IL8

90

Bacterial infection

0.64

(0.39 to 0.84)

0.62

(0.52 to 0.71)

El-Maghraby 2007

IL8

62

Documented infection

0.71

(0.59 to 0.81)

0.77

(0.58 to 0.89)

Lehrnbecher 2004

IL8

320

Documented infection

0.56

(0.46 to 0.65)

0.79

(0.73 to 0.84)

Lehrnbecher 2004

IL8

500

Documented infection

0.44

(0.35 to 0.54)

0.89

(0.84 to 0.93)

El-Maghraby 2007

MCP

350

Documented infection

0.64

(0.52 to 0.75)

0.92

(0.76 to 0.98)

Hitoglou-Hatzi 2005

tADA

35 U/l

Significant bacterial infection

1.0

(0.88 to 1.0)

1.0

(0.91 to 1.0)

Riikonen 1992

TNF

40

Bacteremia or focal infection

1.0

(0.88 to 1.0)

0.07

(0.03 to 0.15)

Hodge 2006

IL5

17

Positive blood culture

0.5

(0.22 to 0.79)

Could not calculate

Hodge 2006

IL5 and 8 combined

> 17 and > 220

Positive blood culture

1.0

(0.68 to 1.0)

0.87

(0.68 to 0.96)

Soker 2001

IL-2R

Bacteremia

Median (range)

5,230 U/mL (1,120 to 7,600)

1,190 (724 to 5,400)

Soker 2001

TNF-alpha

Bacteremia

8.4

(4.0 to 68.2)

7.8

(3.0 to 37.2)

Secmeer 2007

ESR

Bacteremia

"not statistically significantly different between patients with and without documented infection"

Â